Literature DB >> 28138641

Pathologic tumor response to neoadjuvant chemotherapy in gastroesophageal cancer: what does it mean?

Toshiyuki Kosuga1, Daisuke Ichikawa1, Eigo Otsuji1.   

Abstract

Entities:  

Year:  2016        PMID： 28138641      PMCID： PMC5244799          DOI： 10.21037/tgh.2016.09.08

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  12 in total

1.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

Authors:  Katrin M Sjoquist; Bryan H Burmeister; B Mark Smithers; John R Zalcberg; R John Simes; Andrew Barbour; Val Gebski
Journal:  Lancet Oncol       Date:  2011-06-16       Impact factor: 41.316

2.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Young-Woo Kim; Han-Kwang Yang; Hyun Cheol Chung; Young-Kyu Park; Kyung Hee Lee; Keun-Wook Lee; Yong Ho Kim; Sang-Ik Noh; Jae Yong Cho; Young Jae Mok; Yeul Hong Kim; Jiafu Ji; Ta-Sen Yeh; Peter Button; Florin Sirzén; Sung Hoon Noh
Journal:  Lancet       Date:  2012-01-07       Impact factor: 79.321

3.  Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.

Authors:  Juan Wang; Yan-lan Chai; Tao Wang; Jin-hui Liu; Peng-gao Dai; Zi Liu
Journal:  Exp Mol Pathol       Date:  2015-03-13       Impact factor: 3.362

4.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.

Authors:  A M Mandard; F Dalibard; J C Mandard; J Marnay; M Henry-Amar; J F Petiot; A Roussel; J H Jacob; P Segol; G Samama
Journal:  Cancer       Date:  1994-06-01       Impact factor: 6.860

5.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.

Authors:  Karen Becker; James D Mueller; Christoph Schulmacher; Katja Ott; Ulrich Fink; Raymonde Busch; Knut Böttcher; J Rüdiger Siewert; Heinz Höfler
Journal:  Cancer       Date:  2003-10-01       Impact factor: 6.860

6.  Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas.

Authors:  I Fichtner; W Slisow; J Gill; M Becker; B Elbe; T Hillebrand; M Bibby
Journal:  Eur J Cancer       Date:  2004-01       Impact factor: 9.162

7.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

Authors:  Shinichi Sakuramoto; Mitsuru Sasako; Toshiharu Yamaguchi; Taira Kinoshita; Masashi Fujii; Atsushi Nashimoto; Hiroshi Furukawa; Toshifusa Nakajima; Yasuo Ohashi; Hiroshi Imamura; Masayuki Higashino; Yoshitaka Yamamura; Akira Kurita; Kuniyoshi Arai
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

8.  Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas.

Authors:  T Schmidt; L Sicic; S Blank; K Becker; W Weichert; T Bruckner; T Parakonthun; R Langer; M W Büchler; J-R Siewert; F Lordick; K Ott
Journal:  Br J Cancer       Date:  2014-02-25       Impact factor: 7.640

9.  Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition.

Authors:  Dongsheng Huang; Hongying Duan; Hao Huang; Xiangmin Tong; Yong Han; Guoqing Ru; Like Qu; Chengchao Shou; Zhongsheng Zhao
Journal:  Sci Rep       Date:  2016-02-05       Impact factor: 4.379

10.  Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.

Authors:  Elizabeth C Smyth; Matteo Fassan; David Cunningham; William H Allum; Alicia F C Okines; Andrea Lampis; Jens C Hahne; Massimo Rugge; Clare Peckitt; Matthew Nankivell; Ruth Langley; Michele Ghidini; Chiara Braconi; Andrew Wotherspoon; Heike I Grabsch; Nicola Valeri
Journal:  J Clin Oncol       Date:  2016-06-13       Impact factor: 44.544
View more
  1 in total

1.  Which is the optimal management for locally advanced gastric cancer patients with TRG 0 and 1 after R0 resection?

Authors:  Fei Ma; Yonglei Zhang; Liangqun Peng; Zhandong Zhang; Wei Yang; Junhui Chai; Bin Zhang; Sheqing Ji; Yawei Hua; Xiaobing Chen; Suxia Luo
Journal:  Ann Transl Med       Date:  2020-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.